- Home
- MOLN vs RDZN Comparison
MOLN vs RDZN Comparison
Compare MOLN & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MOLN | RDZN |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 190.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MOLN | RDZN |
|---|---|---|
| Price | $4.15 | $2.26 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | 4.7K | ★ 218.3K |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $48,035,296.00 |
| Revenue This Year | N/A | $40.39 |
| Revenue Next Year | $999.99 | $64.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.42 |
| 52 Week Low | $3.36 | $0.68 |
| 52 Week High | $5.91 | $2.56 |
Technical Indicators
Market Signals| Indicator | MOLN | RDZN |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | 64.71 |
| Support Level | $4.21 | $2.13 |
| Resistance Level | $4.48 | $2.56 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 27.08 | 67.02 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.